Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 6/20/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Andrew Fein?

Andrew S. Fein

Analyst

H.C. Wainwright & Co. , Inc.

Direct Phone: (212) ***-****direct phone

Email: a***@***.com

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

H.C. Wainwright & Co. , Inc.

430 Park Avenue

New York City, New York,10022

United States

Company Description

H.C. Wainwright is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and ...more

Background Information

Employment History

Healthcare Research Effort

Chardan Capital Markets LLC


Managing Director and Senior Biotechnology Analyst Positions

Jefferies & Company , Inc.


Managing Director and Senior Biotechnology Analyst Positions

piper jaffray companies


Senior Analyst

Leerink Partners LLC


Managing Director and Senior Biotechnology Analyst

C. E. Unterberg


Associate

J.P. Morgan & Co.


Web References(122 Total References)


Meet Our Analysts, : H. C. Wainwright & Co.

hcwainwright.com [cached]

Andrew Fein
Managing Director, Senior Healthcare Analyst Andrew Fein is a Managing Director focused on healthcare research at HCW. Mr. Fein has more than a dozen years of biotechnology equity research experience. Previously, Mr. Fein headed the healthcare research effort at Chardan Capital Markets. Prior to working at Chardan, Mr. Fein held Managing Director/Senior Biotechnology Analyst positions at Jefferies, Piper Jaffray and Collins Stewart from 2005 to 2010. Mr. Fein, began his career at J.P. Morgan H&Q and first gained recognition as a Senior Analyst at Leerink Swann. He has received honorable mention numerous times from the Institutional Investor All-America research poll Andrew received his Bachelor of Arts degree from Yale University.


News : H. C. Wainwright & Co.

www.hcwainwright.com [cached]

Andrew Fein Launches Coverage at H.C. Wainwright & Co., LLC
Andrew Fein Joins H.C. Wainwright & Co., LLC as Senior Biotechnology Analyst H.C. Wainwright & Co., LLC Announces Addition of Former Senior Members of Rodman & Renshaw Team


August 2016 - Scrying Biotech

scryingbiotech.com [cached]

Andrew Fein, CYCC, Cyclacel, H.C. Wainwright, Michael Webb, sapacitabine, Scrying Biotech, ScryingBiotech
To say that I was surprised when on August 12th, H.C. Wainwright's analyst Andrew Fein put a price target on CYCC of $173 a share is to understate that by quite a lot. It did, however, get me to thinking about his possible motivations for doing so. That speculative bit of expedience noted, let's see if we can't find some logic in Mr. Fein's generous assessment. And while Andrew Fein's outrageous price target of $173 per share on a (SEAMLESS) homerun might be the most eyebrow raising of all, it too could be a lowball estimate should that dream come true. Andrew Fein, CYCC, Cyclacel, Cyclacel Pharmaceuticals, Fein, H.C. Wainwright


CYCC - Scrying Biotech

scryingbiotech.com [cached]

Andrew Fein, CYCC, Cyclacel Pharmaceuticals, sapacitabine, Scrying Biotech
In an August 22nd article entitled: Cyclacel Pharmaceuticals: What You Don't Know, I mused upon the motivations behind Andrew Fein's $173 price target on an equity that was trading for a scant $4.48 on the day prior to publication. We had Andrew Fein valuing the equity at $60 per share without (SEAMLESS) success. Andrew Fein, CYCC, Cyclacel, H.C. Wainwright, Michael Webb, sapacitabine, Scrying Biotech, ScryingBiotech To say that I was surprised when on August 12th, H.C. Wainwright's analyst Andrew Fein put a price target on CYCC of $173 a share is to understate that by quite a lot. It did, however, get me to thinking about his possible motivations for doing so. That speculative bit of expedience noted, let's see if we can't find some logic in Mr. Fein's generous assessment. And while Andrew Fein's outrageous price target of $173 per share on a (SEAMLESS) homerun might be the most eyebrow raising of all, it too could be a lowball estimate should that dream come true. Andrew Fein, CYCC, Cyclacel, Cyclacel Pharmaceuticals, Fein, H.C. Wainwright


Andrew Fein - Scrying Biotech

scryingbiotech.com [cached]

Andrew Fein
Tap, Tap, Tap Cyclacel Does It Again Andrew Fein, CYCC, Cyclacel Pharmaceuticals, sapacitabine, Scrying Biotech In an August 22nd article entitled: Cyclacel Pharmaceuticals: What You Don't Know, I mused upon the motivations behind Andrew Fein's $173 price target on an equity that was trading for a scant $4.48 on the day prior to publication. We had Andrew Fein valuing the equity at $60 per share without (SEAMLESS) success. Andrew Fein, CYCC, Cyclacel, H.C. Wainwright, Michael Webb, sapacitabine, Scrying Biotech, ScryingBiotech To say that I was surprised when on August 12th, H.C. Wainwright's analyst Andrew Fein put a price target on CYCC of $173 a share is to understate that by quite a lot. It did, however, get me to thinking about his possible motivations for doing so. That speculative bit of expedience noted, let's see if we can't find some logic in Mr. Fein's generous assessment. And while Andrew Fein's outrageous price target of $173 per share on a (SEAMLESS) homerun might be the most eyebrow raising of all, it too could be a lowball estimate should that dream come true. Andrew Fein, CYCC, Cyclacel, Cyclacel Pharmaceuticals, Fein, H.C. Wainwright


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory